RAND > Reports & Bookstore > Occasional Papers > OP-121

HomeGo to RAND HomeReports and Book Store Bookstore Sale: Selected publications 40% off AddThis Social Bookmark Button

Document Information

How Goes the “War on Drugs”?

An Assessment of U.S. Drug Problems and Policy

Cover: How Goes the "War on Drugs"?

By: Jonathan P. Caulkins, Peter H. Reuter, Martin Y. Iguchi, James Chiesa

Presents a concise, accessible, objective view of where the United States has been, now stands, and is going in the future in its long “war on drugs.” The authors assess the success of drug policies to date and review possible reasons why they have not been more successful. They consider the drug war’s “collateral damage” and attempt to understand why alternative policies have not been tried. They also lay out some possible futures for drug problems and policy in the United States. The authors recommend that a mix of three drug control strategies-enforcement, treatment, and prevention-be timed to a drug’s “epidemic cycle.” They further recommend that substance abuse be recognized as a long-term problem and managed for the long term and that cross-state variations in drug policy be viewed by the federal government as a plus rather than a minus. In conclusion, they press for a more dispassionate debate.

See Also:

Support RAND Research — Buy This Product!

Paperback Cover Price: $23.00

Discounted Web Price: $20.70

Pages: 60

ISBN/EAN: 0-8330-3737-4

Free, downloadable PDF file(s) are available below.

Download PDF Full Document

(File size 0.6 MB, 2 minutes modem, < 1 minute broadband)

RAND makes an electronic version of this document available for free as a public service. If you find this information valuable, please consider purchasing a paper copy of the full document to help support RAND research.

Use Adobe Acrobat Reader version 7.0 or higher for the best experience.

Contents

Chapter One:
Introduction

Chapter Two:
How Successful Has the War on Drugs Been?

Chapter Three:
Why Hasn’t the Drug War Been a Greater Success?

Chapter Four:
What About Bonuses and Collateral Damage?

Chapter Five:
Why No Course Corrections?

Chapter Six:
How Might U.S. Drug Problems and Policies Evolve?

Chapter Seven:
How Should U.S. Drug Policies Evolve?

The research described in this report was supported by core RAND Drug Policy Research Center (DPRC) funds provided by The Ford Foundation. The DPRC is co-administered by two research units of the RAND Corporation, RAND Health, and RAND Infrastructure, Safety, and Environment (ISE).

This product is part of the RAND Corporation occasional paper series. RAND occasional papers may include an informed perspective on a timely policy issue, a discussion of new research methodologies, essays, a paper presented at a conference, or a summary of work in progress. All RAND occasional papers undergo rigorous peer review to help ensure that they meet high standards for research quality and objectivity.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit research organization providing objective analysis and effective solutions that address the challenges facing the public and private sectors around the world. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.

* RAND research is conducted across divisions, centers, and projects; these organizational components are represented in the "Related RAND Divisions" section above.

Stay Informed Subscribe to RSS Feeds Search RAND Publications View Cart